Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Safety Follow-up Study to Assess Safety of Prior Treatment With Romosozumab in Children and Adolescents With Osteogenesis Imperfecta

NCT07366086 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT07366086
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07366086 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Safety Follow-up Study to Assess Safety of Prior Treatment With Romosozumab in Children and Adolescents With Osteogenesis Imperfecta
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Recruiting
Start date
March 18, 2026
Completion date
April 19, 2028
Enrollment
71 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

osteogenesis imperfecta